Lead Plaintiff Deadline is August 5, 2019

NEW YORK and SAN DIEGO, June 10, 2019 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a federal securities class action lawsuit has been filed in the United States District Court for the Southern District of California on behalf of investors that acquired Heron Therapeutics, Inc. (“Heron Therapeutics” or the “Company”) (NASDAQ: HRTX) securities between October 31, 2018 and April 30, 2019, inclusive (the “Class Period”).

Investors who purchased the shares of Heron Therapeutics, Inc. are urged to contact the firm immediately at classmember@whafh.com or (800) 575-0735 or (212) 545-4774. You may obtain additional information concerning the action on our website www.whafh.com.

If you have incurred losses in the shares of Heron Therapeutics, Inc., you may, no later than August 5, 2019, request that the Court appoint you lead plaintiff of the proposed class. Please contact Wolf Haldenstein to learn more about your rights as an investor in Heron Therapeutics, Inc.  

## Follow the firm and learn about newly filed cases on Twitter and Facebook. ##

The filed complaint   alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors:

• that the Company had failed to include adequate Chemistry, Manufacturing, and Controls and non-clinical information in its New Drug Application (“NDA”) with the U.S. Food and Drug Administration (“FDA”) for HTX-011;
   
• the foregoing increased the likelihood that the FDA would not approve the Company’s NDA for HTX-011; and
   
• as a result, defendants’ public statements were materially false and/or misleading at all relevant times.

On May 1, 2019, the Company confirmed receipt of a Complete Response Letter from the FDA in which the FDA was unable to approve the Company’s New Drug Application for a new postoperative pain medication it had been developing, due to the need for additional information.

On this news, shares of Heron Therapeutics fell $3.93 per share, or over 18%, to close at $17.75 on May 1, 2019.

Wolf Haldenstein Adler Freeman & Herz LLP  has extensive experience in the prosecution of securities class actions and derivative litigation in state and federal trial and appellate courts across the country.  The firm has attorneys in various practice areas; and offices in New York, Chicago and San Diego.  The reputation and expertise of this firm in shareholder and other class litigation has been repeatedly recognized by the courts, which have appointed it to major positions in complex securities multi-district and consolidated litigation.

If you wish to discuss this action or have any questions regarding your rights and interests in this case, please immediately contact Wolf Haldenstein by telephone at (800) 575-0735, via e-mail at classmember@whafh.com, or visit our website at  www.whafh.com.

Contact:

Wolf Haldenstein Adler Freeman & Herz LLP
Kevin Cooper, Esq.
Gregory Stone, Director of Case and Financial Analysis
Email: gstone@whafh.com, kcooper@whafh.com or classmember@whafh.com
Tel: (800) 575-0735 or (212) 545-4774

Attorney Advertising. Prior results do not guarantee or predict a similar outcome.